Compare Ascendis Pharma A/S (ASND) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs PAGSEG Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while PAGSEG Inc trades at $9.23 (market cap $2.59B). The key difference: Ascendis Pharma A/S is far larger — about 6.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.24% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAGS | |
|---|---|---|
Market Cap | $17.74B | $2.59B |
Sector | Health | Technology |
52-Week High | $277.18 | $12.00 |
52-Week Low | $163.32 | $7.75 |
Enterprise Value | $18.11B | $10.22B |
Dividend Yield | — | 11.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PAGS trades at $9.25, up 2.78% with neutral technical indicators showing support at $9 and resistance at $9. The stock presents strong value fundamentals with a P/E of 6.55 and P/B of 0.92, supported by solid profitability including 10.4% net margins and 14.52% ROE. Recent earnings showed mixed results with a Q1 2026 miss but Q4 2025 beat, while the company maintains robust cash flow generation of $7.56B from operations.
The investment case centers on deep valuation discounts and Brazil's rate-cutting cycle potential, though execution risks and competitive pressures remain. Analyst consensus is strongly bullish with 62.5% buy ratings, viewing current levels as attractive for long-term investors given the company's banking and credit expansion trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
